Short-term clinical outcomes of open, laparoscopic, and robotic-assisted rectal resections: a multicenter real-world evidence study from Indian collaborative group on rectal resections (ICGRR)

开放式、腹腔镜式和机器人辅助直肠切除术的短期临床结果:来自印度直肠切除术协作组 (ICGRR) 的多中心真实世界证据研究

阅读:1

Abstract

This multi-centric real-world study was carried out to assess the perioperative and histopathological clinical outcomes of rectal resections employing open, laparoscopic, and robotic-assisted techniques. A retrospective chart review was undertaken for patients who underwent rectal resections for Stages I, II, and III rectal cancer (RC) between April 2012 and August 2023. All surgical procedures were performed with the principles of total mesorectal excision (TME) or partial mesorectal excision (for tumors located higher in the rectum). The study analyzed data from 829 patients of which 314 were in the robotic-assisted group (RAS), 206 in the laparoscopic surgery group (LG), and 309 in the open-surgery group (OG). The TNM staging and location of RC were evenly distributed across the three groups. The RAS group had a significantly lower length of hospital stay than LG and OG. Compared to LG and OG, the RAS group had less blood loss and postoperative complications, but significantly longer mean operating room time. The conversion rate of the RAS group was significantly lower than that of the LG group (p = 0.03). In comparison to the OG and LG groups, the RAS group had significantly lower (p < 0.05) rates of positive circumferential resection margin (CRM). Adjuvant treatment was administered in the RAS group significantly earlier (median, 24.5 days, IQR 18-37) compared to the LG (median, 31 days, IQR 23-41) and OG (median, 32.5 days, IQR 27-42). This largest multi‑centric study by the ICRR group has validated the value of a relatively newer technology like RAS in real-world Indian settings for rectal resections.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。